Maria Eklind-Cervenka is Chief Medical Officer of Inceptua

Maria Eklind-Cervenka is the new Chief Medical Officer of Inceptua Group
Maria Eklind-Cervenka is the new Chief Medical Officer of Inceptua Group

Maria Eklind-Cervenka is the new Chief Medical Officer of Inceptua Group.

Maria joins Inceptua from Sobi where she held the position of Head of Global Medical Affairs, Specialty Care. Maria has led several successful medical strategy and implementation efforts. She has broad experience steering international teams, both at Sobi and in previous roles at Astra-Zeneca and Boehringer-Ingelheim. Maria is a specialist in cardiology and internal medicine, and has practiced at leading hospitals in Sweden.

In her new role as Chief Medical Officer of Inceptua, Maria’s core focus will be on supporting Inceptua’s Commercial Products unit as it expands its reach into new markets and therapy areas.

Inceptua is a pharmaceutical and service company helping pharma and biotech companies throughout the entire product lifecycle. Their core focus areas are clinical services, pre-approval and expanded access programs as well as commercialisation of specialty care and rare disease products. Inceptua is headquartered in Luxembourg and has global operations with offices in Europe, USA and Asia.

The Pf Power List: Who is shaping the pharma & healthcare sector?

Alan Raffensperger, CEO, Inceptua Group said, “With Maria joining we are increasing our Medical Leadership, continuing to develop our platform as the partner of choice for pharma and biotech companies, while ensuring we keep patient safety at the heart of our operations.”

Maria Eklind-Cervenka new Chief Medical Officer of Inceptua said, “I’m delighted to be joining Inceptua. My professional focus has always been about helping patients get the right treatment, and this is exactly what Inceptua is there to support.”

EVP of Commercial Products at Inceptua, Stefan Fraenkel says: “The recruitment of Maria, underlines our drive to be a leading pharma partner supporting throughout the product journey. We are able to assume partial or full product responsibility, and our full company offering spans the life-cycle, from trials, through pre-approval and market access, to product launch, and the successful marketing of speciality and rare disease products.”